Your browser doesn't support javascript.
Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients.
Canti, Lorenzo; Ariën, Kevin K; Desombere, Isabelle; Humblet-Baron, Stéphanie; Pannus, Pieter; Heyndrickx, Leo; Henry, Aurélie; Servais, Sophie; Willems, Evelyne; Ehx, Grégory; Goriely, Stanislas; Seidel, Laurence; Michiels, Johan; Willems, Betty; Goossens, Maria E; Beguin, Yves; Marchant, Arnaud; Baron, Frédéric.
  • Canti L; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
  • Ariën KK; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000 Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • Desombere I; Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Humblet-Baron S; Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium.
  • Pannus P; Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Heyndrickx L; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000 Antwerp, Belgium.
  • Henry A; Department of medicine, division of Hematology, CHU of Liège, Liège, Belgium.
  • Servais S; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium; Department of medicine, division of Hematology, CHU of Liège, Liège, Belgium.
  • Willems E; Department of medicine, division of Hematology, CHU of Liège, Liège, Belgium.
  • Ehx G; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
  • Goriely S; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.
  • Seidel L; Department of Biostatistics, University Hospital of Liège, Liège, Belgium.
  • Michiels J; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000 Antwerp, Belgium.
  • Willems B; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000 Antwerp, Belgium.
  • Goossens ME; Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
  • Beguin Y; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium; Department of medicine, division of Hematology, CHU of Liège, Liège, Belgium.
  • Marchant A; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.
  • Baron F; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium; Department of medicine, division of Hematology, CHU of Liège, Liège, Belgium. Electronic address: f.baron@uliege.be.
Cancer Cell ; 40(4): 335-337, 2022 04 11.
Article in English | MEDLINE | ID: covidwho-1682960
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cancer Cell Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: J.ccell.2022.02.005

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cancer Cell Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: J.ccell.2022.02.005